LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Vaxart Inc

Fechado

0.4 2.56

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.39

Máximo

0.4

Indicadores-chave

By Trading Economics

Rendimento

-3.6M

-16M

Vendas

5.7M

21M

EPS

-0.07

Margem de lucro

-74.684

Funcionários

105

EBITDA

3.7M

-8.6M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+400% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

10M

103M

Abertura anterior

-2.16

Fecho anterior

0.4

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Vaxart Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de jun. de 2025, 20:45 UTC

Ganhos

Broadcom 2Q Sales Climb on Booming AI Demand

5 de jun. de 2025, 23:45 UTC

Conversa de Mercado

Nikkei May Decline as Caution Over U.S. Economy Continues -- Market Talk

5 de jun. de 2025, 23:44 UTC

Conversa de Mercado

Gold Edges Higher on Weak U.S. Data -- Market Talk

5 de jun. de 2025, 23:30 UTC

Conversa de Mercado

NZME Cost Cuts Can Cushion Effect of Weak Market -- Market Talk

5 de jun. de 2025, 21:32 UTC

Ganhos

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

5 de jun. de 2025, 20:45 UTC

Ganhos

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 de jun. de 2025, 20:24 UTC

Ganhos

Broadcom Stock Falls Despite Earnings Beat From AI Chip Maker -- Barrons.com

5 de jun. de 2025, 20:15 UTC

Ganhos

Broadcom 2Q Cont Ops EPS $1.03 >AVGO

5 de jun. de 2025, 20:15 UTC

Ganhos

Broadcom 2Q Rev $15B >AVGO

5 de jun. de 2025, 20:15 UTC

Ganhos

Broadcom 2Q Net $4.97B >AVGO

5 de jun. de 2025, 20:15 UTC

Ganhos

Broadcom 2Q Adj EPS $1.58 >AVGO

5 de jun. de 2025, 20:15 UTC

Ganhos

Broadcom 2Q EPS $1.03 >AVGO

5 de jun. de 2025, 20:15 UTC

Ganhos

Broadcom Sees 3Q Rev $15.8B >AVGO

5 de jun. de 2025, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Constellation Energy: Transaction Is Expected to Close in the 4Q >CEG

5 de jun. de 2025, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Constellation Energy: Calpine Deal Clears Texas Regulatory Review

5 de jun. de 2025, 20:11 UTC

Aquisições, Fusões, Aquisições de Empresas

Constellation Energy: With Approval From PUCT Secured, Transaction Awaits Clearance From NY State Public Service Commission, Federal Energy Regulatory Commission and DOJ >CEG

5 de jun. de 2025, 19:22 UTC

Conversa de Mercado

Oil Futures Resume Upward Moves -- Market Talk

5 de jun. de 2025, 19:00 UTC

Conversa de Mercado

U.S. Natural Gas Settles Lower in Choppy Trade -- Market Talk

5 de jun. de 2025, 18:32 UTC

Conversa de Mercado

Gold Slips After Trump-Xi Call -- Market Talk

5 de jun. de 2025, 18:26 UTC

Ganhos

These Stocks Are Moving the Most Today: Broadcom, Tesla, Circle, Brown-Forman, MongoDB, Planet Labs, ChargePoint, Ciena, and More -- Barrons.com

5 de jun. de 2025, 18:06 UTC

Conversa de Mercado

Transpacific Ship Freight Rates Spike on China Tariff Truce -- Market Talk

5 de jun. de 2025, 16:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Vallourec Completes The Acquisition Of Thermotite Do Brasil >VK.FR

5 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

5 de jun. de 2025, 16:18 UTC

Conversa de Mercado

U.S. Natural Gas Market Shrugs Off Big Storage Build -- Market Talk

5 de jun. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

5 de jun. de 2025, 16:12 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

5 de jun. de 2025, 16:12 UTC

Conversa de Mercado

Copper Prices Rise on Positive Signals From Trump on China Trade Talks -- Market Talk

5 de jun. de 2025, 16:03 UTC

Conversa de Mercado

U.S. Diesel, Gasoline Futures Pick Back Up -- Market Talk

5 de jun. de 2025, 15:49 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

Comparação entre Pares

Variação de preço

Vaxart Inc Previsão

Preço-alvo

By TipRanks

400% parte superior

Previsão para 12 meses

Média 2 USD  400%

Máximo 2 USD

Mínimo 2 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Vaxart Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

1

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.4007 / 0.4252Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.